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Objective To determine the effects of varying inoculum size on in vitro susceptibility of SHV extended-
spectrum b-lactamase (ESBL)-producing Klebsiella pneumoniae isolates to cefepime and cefpirome compared
to previously established cephalosporins and aztreonam.
Methods Antibiotic susceptibilities were determined by disk diffusion test, the MIC broth microdilution
method, and time–kill studies with two different inocula of 105 and 107 CFU/mL. The strains were classified
into four groups acccording to the type of b-lactamase they produce: SHV-2, SHV-5, SHV-12, and ESBL-
negative klebsiellae.
Results The antibacterial activities of cefpirome and cefepime were comparable to that of cefotaxime,
but were significantly greater than those of ceftazidime and aztreonam. An inoculum effect was detected
for all broad-spectrum cephalosporins, but it was more pronounced with cefpirome and cefepime
compared to older cephalosporins. The disk diffusion test proved to be not sensitive enough for the detection
of an inoculum effect, particularly for cefepime.
Conclusions The present study found that most SHV-producing klebsiellae have MICs of cefpirome that
imply susceptibility at the moderate inoculum size, in spite of the fact that, according to the NCCLS,
all ESBL producers should be considered resistant to all cephalosporins, independent of MIC values. With a
high inoculum, most of the strains seemed to be resistant to both antibiotics. Furthermore, the bactericidal
activities of cefpirome and cefepime against isogenic Escherichia coli strains producing SHV-2, SHV-4
and SHV-5 b-lactamases, respectively, were also inoculum dependent. Bactericidal activity against SHV-4
and SHV-5 b-lactamase producers was obtained only at the moderate inoculum, whereas the SHV-2
b-lactamase producer was efficiently killed with both antibiotics, regardless of the inoculum size.
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INTRODUCTION
The plasmid-mediated extended-spectrum b-lactamases
(ESBLs) confer resistance to oxymino-cephalosporins, such
as cefotaxime, ceftazidime, and ceftriaxone, and to monobac-
tams such as aztreonam. These enzymes occur predominantly in
Klebsiella species [1] and Escherichia coli, but they may also be
present in other genera of the family Enterobacteriaceae, such as
Citrobacter, Serratia, Proteus, Salmonella, and Enterobacter [2–5].
These enzymes are frequently derived from either a TEM- or
SHV-related b-lactamase. They hydrolyze oxymino-b-lactams
at rates at least 10% of that observed for benzylpenicillin, in
contrast to the parental TEM-1 or SHV-1 enzymes, for which
the expanded-spectrum b-lactams are poor substrates. As a
result, MICs of the newer cephalosporins and aztreonam are
elevated, although clinical resistance is not always evident [6,7].
Since the first discovery in Germany [8], ESBLs have been
reported in many countries of the world [9].
Cefepime and cefpirome are new fourth-generation cepha-
losporins which were believed to have enhanced activity against
ESBL- and AmpC-type b-lactamase-producing Enterobacter-
iaceae, but, according to recent reports, their activity is seriously
compromised by ESBLs [10].
The aim of this investigation was to determine the effect of
varying bacterial suspension density on the in vitro antibacterial
activities of cefpirome and cefepime against Klebsiella pneumo-
niae strains with previously characterised and sequenced SHV
ESBLs [11,12], compared to non-ESBL K. pneumoniae strains.
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MATERIALS AND METHODS
Bacteria
The experiments were performed on a set of K. pneumoniae
strains with previously characterised and sequenced b-lacta-
mases [11,12] which comprise: 10 SHV-5 b-lactamase-produ-
cing strains; 20 SHV-2 and one SHV-2a b-lactamase-producing
strains; seven SHV-12 b-lactamase-producing strains; and 26
isolates highly susceptible to ceftazidime according to the
Kirby–Bauer disk diffusion method (diameter of the inhibi-
tion zones 27 mm) and thus considered to be ESBL
negative.
ESBL-producing K. pneumoniae isolates were collected dur-
ing 1994–95 and 1997 from the Sestre Milosrdnice Hospital and
Dubrava Hospital in Zagreb. ESBL-negative, ceftazidime-sus-
ceptible K. pneumoniae isolates were obtained from the Sestre
Milosrdnice Hospital in Zagreb during 1994–95. All isolates
were identified by conventional biochemical tests.
Reference strains Escherichia coli A15 Rþ, obtained in the
transconjugation experiments and containing plasmids encod-
ing SHV-2, SHV-4 and SHV-5 b-lactamases, respectively, were
used in time–kill studies. Their resistance phenotype is shown in
Table 1.
Detection of ESBLs
Production of ESBLs was determined by comparing ceftazi-
dime MICs with and without clavulanic acid. Strains were
further examined for SHV ESBLs by PCR/Nhe test [13].
Owing to the glycine (position 238) (SHV-non-ESBL) to serine
(position 238) (SHV-ESBL) mutation, only PCR fragments
from the genes coding for SHV-ESBLs are cleaved.
Characterisation of b-lactamases
b-Lactamases were prepared and characterised as described
previously [11].
PCR and sequencing of blaSHVgenes
PCR and sequencing of blaSHV genes was performed as
described previously [13,14].
Susceptibility tests
Kirby^Bauer disk diffusion test
The test was performed with two different inocula of 105 and
107 CFU/mL. Inoculum sizes were verified by serial dilution
and plating techniques [15]. Mueller–Hinton agar was used.
Ceftazidime (30 mg), cefotaxime (30 mg) and ceftriaxone (30 mg)
disks were purchased from the Institute of Immunology
(Zagreb, Croatia). Cefepime (30 mg) and aztreonam (30 mg)
disks were obtained from Becton-Dickinson, Cockeysville,
MD, USA. The test was interpreted according to the NCCLS
[16]. The strains were considered resistant if the zone diameter
was equivalent to or less than 14 mm for ceftazidime, cefotax-
ime and cefepime, equivalent to or less than 13 mm for cef-
triaxone, and equivalent to or less than 15 mm for aztreonam. If
there was no inhibition zone around the disk, the zone diameter
was read as 0.
Determination ofminimum inhibitory concentrations
(MICs)
MICs of ceftazidime, cefotaxime, ceftriaxone, cefpirome, cefe-
pime and aztreonam were determined by the broth microdilu-
tion method in Mueller–Hinton broth, also with two different
inocula of 105 and 107 CFU/mL, as described previously [17].
The MIC breakpoint of 8 mg/L was applied. Antibiotic pow-
ders were obtained from the following sources: ceftazidime,
Pliva, Zagreb, Croatia; cefepime and aztreonam, Bristol
Myers Squibb, Munich, Germany; cefpirome and cefo-
taxime, Hoechst AG, Frankfurt, Germany; and ceftriaxone,
Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany. Escher-
ichia coli 25922 was used as the reference strain for quality
control.
Determination ofminimumbactericidal concentrations
(MBCs)
MBCs of ceftazidime, cefpirome and cefepime were deter-
mined by subculturing the wells that had no visible growth by
removing 10 mL from each clear well and spotting the sample on
an MH agar plate [18] with two different inocula of 105 and
107 CFU/mL. The MBC was defined as the lowest concentra-
tion of the antibiotic that reduced the inoculum by 99.9%
within 24 h.
Table1 Antibiotic susceptibilities (mg/L) of the reference Escherichia coliA15Rþ transconjugant strains
Antimicrobial agent
Escherichia coli A15
RþSHV-2
Escherichia coli A15
RþSHV-4
Escherichia coli A15
RþSHV-5
Escherichia coli A15
R^ (recipient)
Ceftazidime 4 8 128 0.12
Cefotaxime 8 64 16 0.06
Ceftriaxone 16 64 16 0.06
Aztreonam 2 32 128 0.06
Cefpirome 16 64 8 0.03
Cefepime 16 64 16 0.06
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Time^kill studies
Reference strains (Escherichia coli A15 Rþ) producing SHV-2,
SHV-4 and SHV-5 b-lactamases were used in time–kill studies.
A bacterial inoculum in the logarithmic phase of growth was
added to a 25-mL flask containing antibiotic at a concentration
equivalent to the resistance breakpoint (32 mg/L). The bacterial
concentration was adjusted to final concentrations of 105 and
107 CFU/mL. The flasks were incubated in a shaking water
bath at 37 8C, and samples were removed after 2, 4, 6 and 24 h
for enumeration by serial dilution and plating [19]. MICs of
ceftazidime, cefotaxime, ceftriaxone, cefpirome, cefepime and
aztreonam were determined for the regrowth organisms and
compared with those of the initial strains.
RESULTS
Characterisation of b-lactamases
b-Lactamases were characterised and the ESBL genes were
sequenced as described previously [11,12].
SHV-2 b-lactamase was identified based on an isoelectric
point of 7.6 and the point mutation in the open reading frame at
position 238 (glycine! serine).
SHV-2a b-lactamase was identified based on the pI of 7.6 and
point mutations at positions 35 (leucine! glutamine) and 238
(glycine! serine).
SHV-5 b-lactamase was identified based on the pI of 8.2 and
point mutations at positions 238 (glycine! serine) and 240
(glutamic acid! lysine).
SHV-12 b-lactamase was identified based on the pI of 8.2 and
point mutations at positions 35 (leucine! glutamine), 238
(glycine! serine) and 240 (glutamic acid! lysine).
Effect of inoculum size on the antibiotic susceptibilities
When the inoculum size rose from 105 to 107, the SHV-5
producers displayed increases of 0 to 16-fold in the ceftazi-
dime MIC, 0–8-fold for cefotaxime, 0–4-fold for ceftriaxone, 0
to128-fold for aztreonam, 0–256-fold for cefpirome, and 4 to
32-fold for cefepime. Inoculum effects were detected with
cefepime in all strains, and with ceftazidime and cefpirome in
70%, with aztreonam in 50% and with cefotaxime and cef-
triaxone in 40% of SHV-5-producing strains.
With SHV-12 producers, increases in inoculum concentra-
tion over a range of 105107 resulted in increases in MICs of 2
to 8-fold for ceftazidime, 0–8-fold for cefotaxime, 0–2-fold
for ceftriaxone, 0 to 16-fold for aztreonam, 8–256-fold for
cefpirome, and 2 to 32-fold for cefepime. The inoculum
effects were observed with cefpirome and cefepime in all strains,
and with ceftazidime in 85.7%, with aztreonam in 71.42%, with
ceftriaxone in 42.85% and with cefotaxime in 28.57% of the
SHV-12-producing strains.
The MIC of ceftazidime increased 0–128-fold, of cefotaxime
0–16-fold, of ceftriaxone 0–8-fold, of aztreonam 2 to 1024-
fold, of cefpirome 0–128-fold and of cefepime 8 to 256-fold
in SHV-2 producers when comparing the inocula of 105 and
107 CFU/mL. All strains showed inoculum effects for ceftazi-
dime, aztreonam and cefepime, 90.47% for cefpirome, 76.19%
for cefotaxime and 66% for ceftriaxone.
All ESBL-negative klebsiellae showed an increase in cefta-
zidime MIC, 88.46% in cefotaxime, cefepime and aztreonam
MICs, 69.23% in cefpirome MIC and 50% in ceftriaxone MIC
when higher bacterial density was applied.
At the standard inoculum size, cefepime and cefpirome were
visibly more active against SHV-5 and SHV-12 producers than
ceftazidime and aztreonam and equally active as cefotaxime and
ceftriaxone. When the standard inoculum was applied, cefpir-
ome exhibited stronger inhibitory activity against the SHV-5
and SHV-12 producers than SHV-2 producers. At the high in-
oculum, the activities of cefepime and cefpirome were com-
promised more than those of cefotaxime and ceftriaxone. With
107 CFU/mL, cefpirome, cefotaxime and ceftriaxone more
efficiently inhibited SHV-5 producers than cefepime. Ceftazi-
dime and aztreonam had high MICs whatever the inoculum
tested (Table 2). Non-ESBL-producing klebsiellae were uni-
formly susceptible to third- and fourth-generation cephalos-
porins when tested at standard inoculum size. The inoculum
effect was more pronounced with ceftazidime than with other
cephalosporins and aztreonam. Ceftriaxone had stronger anti-
bacterial activity against ESBL-negative klebsiellae than other
cephalosporins at both inoculum strengths (Table 3). The percen-
tage of strains fully susceptible to third- and fourth-generation
cephalosporins with moderate and high inocula is shown in
Table 4.
The effect of inoculum density on the antibacterial activity of
cephalosporins was also tested by disk diffusion. The diameters
of the inhibition zones obtained with 105 and 107 CFU/mL
were similar, independent of the antibiotic and the type of
b-lactamase (results not shown).
At the standard inoculum size, cefpirome was slightly more
active against SHV-12 producers than cefotaxime and ceftriax-
one, and markedly more active than ceftazidime, cefuroxime
and cephalexin. Declines in the inhibitory activities of cefepime
and cefpirome were more significant when the inoculum con-
centration was raised to 107 CFU/mL than those of cefotaxime
and ceftriaxone. A large increase in the MIC of cefepime
occurred with all three types of b-lactamase producer.
The inoculum effect was strain dependent regardless of the
type of b-lactamase. It was more apparent when the microdilu-
tion test was applied compared to the disk diffusion procedure.
MBCs of ceftazidime, cefpirome and cefepime were usually
the same as MICs of those antibiotics, or at the most two
dilutions higher than MICs, regardless of the inoculum density
or the type of b-lactamase (results not shown).
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 626–635
628 Clinical Microbiology and Infection, Volume 7 Number 11, November 2001
Analysis of time–kill curves (Figure 1) showed that the SHV-
5-producing Escherichia coli strain exposed to ceftazidime and
cefpirome at the breakpoint concentration had regrowth after
24 h regardless of the initial bacterial concentration. At the high
initial inoculum there was no evidence of antibacterial activity.
The SHV-2-producing strain was efficiently killed with
cefepime and cefpirome at the breakpoint concentration
regardless of the starting inoculum size (Figure 2). This could
be explained by the fact that the cefpirome and cefepime MICs
of that strain were significantly below the breakpoint concen-
tration. Ceftazidime was immediately bactericidal at the mod-
erate inoculum size. At the high inoculum size, there were still
100 colonies after 24 h. With the SHV-4 producer, there was a
high rate of killing by cefpirome and cefepime at the moderate
inoculum. At the high inoculum, both antibiotics were inef-
fective (Figure 3).
Table 2 Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against SHV-ESBL-producing Klebsiella pneumoniae strains, compared
to older cephalosporins
MIC (mg/L)
Ceftazidime Cefotaxime Ceftriaxone Aztreonam Cefpirome Cefepime
Strain no. 105 107 105 107 105 107 105 107 105 107 105 107
SHV-5
635-1 1024 >1024 64 64 32 32 >1024 >1024 8 32 32 256
4512 128 256 4 8 16 32 64 >1024 8 4 16 128
4554 >1024 >1024 64 64 16 64 >1024 >1024 16 32 32 >1024
1960 128 256 8 32 4 16 128 >1024 23 32 32 512
135 64 256 4 4 8 8 >1024 >1024 2 4 16 128
3150 >1024 >1024 2 8 16 8 >1024 >1024 16 4 64 >1024
4467 1024 >1024 64 32 128 32 1024 >1024 16 8 64 512
4199 64 512 16 8 64 128 1024 >1024 1 64 16 64
591 16 256 16 128 64 32 8 >1024 64 64 64 512
4946 512 256 16 16 64 32 >1024 >1024 0.5 128 8 128
SHV-12
586 128 256 8 8 6 8 64 >1024 1 64 32 64
1980 64 256 4 4 64 32 128 >1024 1 32 16 64
2570 128 >1024 32 16 256 128 >1024 >1024 1 128 32 >1024
564-2 64 512 4 8 64 64 64 >1024 4 64 32 256
315-8 >1024 128 64 32 16 32 >1024 >1024 4 32 8 64
4187 128 256 16 128 32 64 128 >1024 1 64 16 512
1935 64 256 16 8 4 8 512 >1024 0.5 128 64 128
SHV-2þ 2a
3993 128 256 6 32 16 64 32 >1024 64 64 8 512
4448-2 64 256 4 16 2 16 16 >1024 4 8 8 256
4400 512 512 4 32 64 64 512 >1024 16 64 16 >1024
1294 256 >1024 64 128 64 128 256 >1024 32 64 32 256
4204 32 256 16 8 128 128 16 >1024 32 256 32 512
3992 32 256 16 16 16 128 16 >1024 32 256 8 256
4559 32 128 16 32 4 32 32 >1024 4 4 2 256
1893 32 256 32 16 128 256 64 >1024 8 16 4 1024
4473 128 >1024 64 32 32 32 32 >1024 64 256 16 256
840 32 512 16 128 64 128 64 >1024 16 512 8 512
981 64 512 32 64 64 64 64 >1024 64 1024 8 >1024
467 128 1024 64 128 128 256 64 >1024 64 1024 8 >1024
1543 16 512 16 32 16 8 16 >1024 64 512 16 1024
118 8 1024 8 64 32 64 8 >1024 16 1024 8 >1024
166 128 >1024 64 128 256 128 256 >1024 64 1024 32 512
1381 32 1024 32 128 64 128 64 >1024 32 256 8 512
1372 32 128 16 16 8 16 8 >1024 64 256 8 256
059 8 128 8 16 16 64 8 >1024 16 256 4 >1024
4667-1 4 128 2 32 4 16 1 >1024 1 128 4 128
1401 4 256 16 8 16 8 4 >1024 8 128 2 >1024
1022 128 256 32 64 8 32 8 >1024 64 1024 8 1024
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DISCUSSION
It is a well-known fact that ESBL-producing bacteria exhibit a
pronounced inoculum effect against broad-spectrum cephalos-
porins such as ceftazidime, cefotaxime, ceftriaxone and cefo-
perazone [20,21], but there are not many reports on their
inoculum effect against the fourth-generation cephalosporins
cefepime and cefpirome [22].
Numerous in vitro studies have shown the enhanced activity
of cefepime and cefpirome against Gram-negative organisms
resistant to other extended-spectrum cephalosporins. However,
the in vitro activity of fourth-generation cephalosporins is
significantly decreased by the production of ESBLs by Enter-
obacteriaceae. This activity is greatly influenced by which
specific ESBL is present. Although the in vitro activities of
cefepime and cefpirome against most ESBL-producing Enter-
obacteriaceae exceed that of ceftazidime (except CTX-M
type), they may be similar to that of cefotaxime against a
number of strains. Since cefotaxime has been shown not to
be generally efficient against infections caused by ESBL-produ-
cing Enterobacteriaceae despite MICs in the susceptible range,
the clinical efficacy of the fourth-generation cephalosporins
remains questionable at this time. Data from in vitro studies
suggest that clinical efficacy will probably depend upon which
particular ESBL is being produced by the strain involved [10].
However, according to the last NCCLS edition, ESBL-produ-
cing strains should be considered resistant to all cephalosporins
independent of MIC values [17], but in the routine laboratory
the important question is whether the organism is susceptible,
and certainly in the early stages, it is not known and not relevant
whether the organism is an ESBL producer. For that reason, it is
very important to use the suitable inoculum for the suscept-
ibility testing of any organisms, including ESBL producers. In
previous studies, it was determined that cefepime is at least two-
fold more active against bacteria producing SHV-2, SHV-3 or
SHV-4 b-lactamase than other cephalosporins, including cefo-
taxime, cefpirome, ceftazidime and ceftriaxone [23], but the
study was performed with laboratory Escherichia coli strains
harboring the mentioned ESBLs. Clinical K. pneumoniae isolates
may have other resistance mechanisms, such as lack of porins,
which could influence the antibacterial activity of fourth-
generation cephalosporins.
Table 3 Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against ESBL-negativeKlebsiellapneumoniae strains, compared to older
cephalosporins
MIC (mg/L)
Ceftazidime Cefotaxime Ceftriaxone Aztreonam Cefpirome Cefepime
105 107 105 107 105 107 105 107 105 107 105 107
2317 1 32 0.12 1 0.12 0.25 0.12 8 0.5 16 2 16
3044 0.12 2 0.12 1 0.25 2 0.12 0.5 0.12 2 0.12 8
4525 0.12 8 0.25 0.5 0.12 0.12 0.12 1 0.5 0.5 1 4
4397 0.25 8 0.06 0.25 <0.06 0.06 0.12 4 0.25 0.5 0.25 2
4677 0.12 8 0.06 0.5 0.06 0.25 1 1 0.25 1 0.25 16
4388 0.12 32 0.12 0.25 <0.06 0.12 0.06 4 0.25 4 0.5 4
4198 0.06 16 0.25 16 <0.06 1 0.25 1 0.5 0.25 0.25 1
4197 1 32 1 0.5 <0.06 1 0.25 4 0.5 0.5 1 2
4267 0.06 8 0.5 0.5 0.12 0.06 0.12 0.5 0.12 0.12 0.5 1
4275 0.03 8 0.12 0.5 0.06 1 0.06 1 0.12 <0.06 0.25 0.5
4532 0.06 8 1 16 <0.06 2 1 1 0.25 <0.06 0.12 0.25
4425 0.06 16 0.5 8 1 2 0.12 1 0.06 0.12 0.12 1
4573 2 16 0.06 0.25 0.12 0.12 0.12 2 0.25 4 0.5 2
4843 1 2 0.06 0.25 0.12 0.12 0.12 4 0.25 1 0.12 0.5
4357 0.06 8 0.06 0.5 0.12 0.06 0.12 1 1 <0.06 0.25 0.5
4456 0.03 32 0.06 0.25 <0.06 <0.06 0.06 4 0.06 0.5 0.25 8
4146 0.5 8 0.25 0.5 0.12 0.5 0.5 2 0.12 16 0.25 0.5
4349 0.25 16 0.5 8 0.12 0.5 1 2 0.5 0.25 0.5 0.5
5043 0.5 64 0.5 1 0.12 1 2 2 0.12 0.5 0.25 4
5104 0.25 16 0.25 0.12 <0.06 1 1 4 0.06 0.5 0.12 2
5210 0.12 8 0.12 0.25 <0.06 0.25 0.5 4 0.06 8 0.5 8
5106 1 4 0.03 2 1 0.06 0.12 1 0.06 0.25 0.5 1
5170 0.5 64 0.12 0.5 0.12 0.25 0.25 8 0.06 4 0.5 4
5328 0.03 16 0.25 32 0.12 0.12 0.5 4 0.06 4 0.5 1
5023 0.25 16 0.03 0.5 <0.06 <0.06 0.12 0.25 0.06 0.25 0.25 1
4909 0.06 16 0.12 32 0.12 0.06 0^12 2 0.06 0.12 0.25 0.25
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The present study found that most SHV-producing klebsiel-
lae were indeed susceptible to cefpirome at the low and
moderate inoculum size and to cefepime at the low inoculum
size according to the MIC determination. With a high inocu-
lum, most of the strains were resistant to both antibiotics.
Discrepancies were found for cefepime between the results
of the MIC determination by broth microdilution and the disk
diffusion procedure when a high inoculum was applied. The
size of the inhibition zones indicated susceptibility, whereas
MICs were above the susceptibility breakpoint. In principle, the
disk diffusion test was not found to be an accurate method for
the detection of inoculum effects against SHV-ESBL-produ-
cing klebsiellae.
The effect of inoculum density was observed to be strain
dependent. It was more pronounced when the MIC for the
particular strain was lower. The possible explanation is that the
strains for which the cephalosporin MICs are lower produce less
b-lactamase. As a result, higher inocula are needed to demon-
strate abrogation of the inhibitory effect of a cephalosporin.
The inoculum effect was clearly observed in our time–kill
studies on the bactericidal effect of cefepime. The drug was
bactericidal with a moderate inoculum but it was either bacter-
iostatic or permitted regrowth of organisms with higher starting
bacterial concentrations. There was no evidence that this
regrowth was associated with emergence of a resistant mutant,
since the MIC of cefepime for the regrowth organism remained
the same as for the initial strain (results not shown). Factors
causing an inoculum effect in vitro have not been clearly
defined. However, it is most commonly associated with b-
lactam antibiotics, and probably represents greater hydrolysis by
the cumulative activity of b-lactamase. It is more difficult to
explain the inoculum effect in non-ESBL klebsiellae. However,
they all produce chromosomal SHV-1 b-lactamase, which does
not hydrolyze new cephalosporins but, if produced in large
amounts, may occupy the periplasmic space and mechanically
prevent the b-lactam antibiotics from reaching their target
penicillin-binding protein molecules. The therapeutic signifi-
cance of an observed inoculum effect is also uncertain. In
theory, the inoculum effect may be an important factor in
the management of infections involving high bacterial con-
centrations. The therapeutic failures of fourth-generation
cephalosporins in the treatment of infections caused by
ESBL-producing bacteria could be in part explained by a high
density of bacteria at the infection site, bearing in mind that
there may be other factors contributing to this, such as the lack
of porins.
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